Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease

Christina Kratschmer. MD, PhD

&

Characterizing the pre‐clinical phase of inflammatory bowel disease

Quazim Alayo, MD, MMSc

Please Contact Beth Buschard-Steiger (bbuscha@wustl.edu) for Zoom Details